Catalyst Brief

← Calendar

Readoutin 135d

Vertex Pharmaceuticals Incorporated — ELX/TEZ/IVA

Phase 3 primary completion: Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del.

Date
Apr 2027
Type
Readout
Indication
Cystic Fibrosis

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Vertex Pharmaceuticals Incorporated

  1. Jan2027